These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. Nordestgaard BG; Langsted A J Lipid Res; 2016 Nov; 57(11):1953-1975. PubMed ID: 27677946 [TBL] [Abstract][Full Text] [Related]
4. NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. Tsimikas S; Fazio S; Ferdinand KC; Ginsberg HN; Koschinsky ML; Marcovina SM; Moriarty PM; Rader DJ; Remaley AT; Reyes-Soffer G; Santos RD; Thanassoulis G; Witztum JL; Danthi S; Olive M; Liu L J Am Coll Cardiol; 2018 Jan; 71(2):177-192. PubMed ID: 29325642 [TBL] [Abstract][Full Text] [Related]
5. Elevated Lipoprotein(a) Does Not Cause Low-Grade Inflammation Despite Causal Association With Aortic Valve Stenosis and Myocardial Infarction: A Study of 100,578 Individuals from the General Population. Langsted A; Varbo A; Kamstrup PR; Nordestgaard BG J Clin Endocrinol Metab; 2015 Jul; 100(7):2690-9. PubMed ID: 25938632 [TBL] [Abstract][Full Text] [Related]
6. Effect of APOE ε Genotype on Lipoprotein(a) and the Associated Risk of Myocardial Infarction and Aortic Valve Stenosis. Kritharides L; Nordestgaard BG; Tybjærg-Hansen A; Kamstrup PR; Afzal S J Clin Endocrinol Metab; 2017 Sep; 102(9):3390-3399. PubMed ID: 28651346 [TBL] [Abstract][Full Text] [Related]
7. Current and future role of lipoprotein(a) in preventive cardiology. Berman AN; Blankstein R Curr Opin Cardiol; 2019 Sep; 34(5):514-518. PubMed ID: 31261178 [TBL] [Abstract][Full Text] [Related]
8. Triglyceride-rich lipoproteins and HDL: what do recent trials tell us? Stock J Atherosclerosis; 2013 Jun; 228(2):329-31. PubMed ID: 23623013 [No Abstract] [Full Text] [Related]
9. What is the ultimate test that lowering lipoprotein(a) is beneficial for cardiovascular disease and aortic stenosis? Hung MY; Tsimikas S Curr Opin Lipidol; 2014 Dec; 25(6):423-30. PubMed ID: 25340480 [TBL] [Abstract][Full Text] [Related]
10. Lipoprotein(a) is a risk factor for aortic and mitral valvular stenosis in peripheral arterial disease. Hojo Y; Kumakura H; Kanai H; Iwasaki T; Ichikawa S; Kurabayashi M Eur Heart J Cardiovasc Imaging; 2016 May; 17(5):492-7. PubMed ID: 26758409 [TBL] [Abstract][Full Text] [Related]
11. Editorial: Lipoprotein (a), More than Just Cholesterol? Kolovou GD; Katsiki N; Mikhailidis DP Curr Med Chem; 2017; 24(10):952-956. PubMed ID: 28571555 [No Abstract] [Full Text] [Related]
12. Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis. Yeang C; Wilkinson MJ; Tsimikas S Curr Opin Cardiol; 2016 Jul; 31(4):440-50. PubMed ID: 27205885 [TBL] [Abstract][Full Text] [Related]
13. [The Current Significance of Measuring HDL-Cholesterol in Cardiovascular Risk Assessment]. Wallimann-Annema W Praxis (Bern 1994); 2021; 110(7):383-390. PubMed ID: 34019448 [TBL] [Abstract][Full Text] [Related]
14. Epidemiology, pathophysiology and therapeutic implications of lipoprotein(a) in kidney disease. Kronenberg F Expert Rev Cardiovasc Ther; 2004 Sep; 2(5):729-43. PubMed ID: 15350174 [TBL] [Abstract][Full Text] [Related]